These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 21403462)

  • 1. [A case of aggressive multiple myeloma].
    Oda Y; Ooi S; Endoh A; Urushidani Y; Nakamura R; Adachi K
    Gan To Kagaku Ryoho; 2011 Mar; 38(3):489-92. PubMed ID: 21403462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
    Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Multiple myeloma of the IgD-lambda type invading CNS].
    Kitamura K; Takeuchi J; Kanbe E; Oka H; Saiki M; Aikawa S; Kura Y; Hatta Y; Yamazaki T; Ito T; Sawada U; Horie T
    Rinsho Ketsueki; 2004 Oct; 45(10):1124-8. PubMed ID: 15553049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib therapy following first relapse.
    Orlowski RZ;
    Oncology (Williston Park); 2005 Jan; 19(1):23-6. PubMed ID: 15743149
    [No Abstract]   [Full Text] [Related]  

  • 5. Three cases of bortezomib-resistant multiple myeloma with extramedullary masses.
    Moriuchi M; Ohmachi K; Kojima M; Tsuboi K; Ogawa Y; Nakamura N; Ando K
    Tokai J Exp Clin Med; 2010 Apr; 35(1):17-20. PubMed ID: 21319020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report.
    Kaposztas Z; Kahan BD; Katz SM; Van Buren CT; Cherem L
    Transplant Proc; 2009 Dec; 41(10):4407-10. PubMed ID: 20005409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma].
    Takatoku M; Noborio-Hatano K; Takahashi S; Kikuchi S; Mori M; Muroi K; Komatsu N; Ozawa K
    Rinsho Ketsueki; 2004 Feb; 45(2):144-8. PubMed ID: 15045823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
    Mateos MV; Richardson PG; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Schots R; Jiang B; Esseltine DL; Liu K; Cakana A; van de Velde H; San Miguel JF
    J Clin Oncol; 2010 May; 28(13):2259-66. PubMed ID: 20368561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effectiveness of bortezomib and bortezomib-containing programs for the treatment of recurrent and resistant multiple myeloma].
    Mitina TA; Golenkov AK; Kataeva EV; Lutskaia TD; Trifonova EV; Klinushkina EF
    Ter Arkh; 2010; 82(7):57-61. PubMed ID: 20853611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Nonproducing myeloma without evident bone lesion].
    Kawatani T; Maeda N; Hosoda A; Agou H; Nakai K; Kawasaki H
    Rinsho Ketsueki; 1990 Jun; 31(6):842-6. PubMed ID: 2214175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.
    Rodríguez-Martín M; Sáez-Rodríguez M; García-Bustínduy M; Martín-Herrera A; Noda-Cabrera A
    Dermatol Online J; 2008 Nov; 14(11):14. PubMed ID: 19094852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP).
    Eom HS; Kim YK; Chung JS; Kim K; Kim HJ; Kim HY; Jin JY; Do YR; Oh SJ; Suh C; Seong CM; Kim CS; Lee DS; Lee JH
    Ann Hematol; 2010 May; 89(5):489-97. PubMed ID: 20012045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effective combination therapy of bortezomib and dexamethasone for two patients with refractory multiple myeloma].
    Ikeda H; Hayashi T; Nojima M; Yasui H; Ikeda Y; Ishida T; Adachi M; Imai K
    Rinsho Ketsueki; 2005 Apr; 46(4):269-73. PubMed ID: 16444959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Plasmocytic pleural effusion disclosing multiple myeloma].
    Elloumi M; Frikha M; Masmoudi H; Mseddi S; Ben Ayed M; Bouaziz M; Makni F; Souissi T
    Rev Mal Respir; 2000 Apr; 17(2):495-7. PubMed ID: 10859769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.
    Popat R; Oakervee H; Williams C; Cook M; Craddock C; Basu S; Singer C; Harding S; Foot N; Hallam S; Odeh L; Joel S; Cavenagh J
    Br J Haematol; 2009 Mar; 144(6):887-94. PubMed ID: 19183191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Complete remission in multiple myeloma with natural interferon-alpha (HLBI) and melphalan/prednisolone intermittent therapy].
    Ito M; Nakagawa T; Imoto S; Isobe T; Nakao Y
    Rinsho Ketsueki; 1990 Jun; 31(6):847-52. PubMed ID: 2214176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Rapid growth of glioblastoma during therapy for multiple myeloma: case report].
    Sonoda Y; Kumabe T; Umezawa K; Shimizu H; Murakawa Y; Kanamaru R; Yoshimoto T
    No Shinkei Geka; 1998 Aug; 26(8):737-41. PubMed ID: 9744004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple myeloma with multiple and bulky extramedullary plasmacytomas as initial presentation.
    SAWADA T; NAJIMA Y; OHASHI K; KATO I; MIYAZAWA M; NAKANO M; KOBAYASHI T; YAMASHITA T; AKIYAMA H; SAKAMAKI H
    Rinsho Ketsueki; 2009 Nov; 50(11):1635-40. PubMed ID: 20009440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Velcade in multiple myeloma].
    Votiakova OM; Osmanov DSh; Demina EA; Falaleeva NA; Bialik TE; Riabukhina IuE; Timofeeva OL; Gromova EG; Kupryshina NA; Kochergina NV
    Ter Arkh; 2007; 79(7):70-3. PubMed ID: 17802795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
    Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R
    J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.